Table 2

Chemopreventive efficacy of celecoxib on the incidence and multiplicity of AOM-induced colon carcinogenesis in male F344 rats

Experimental groupIncidence (% animals with colon tumors)Multiplicity (no. of colon tumors/rat)
AdenomasAdenocarcinomasTotalaAdenomasAdenocarcinomasTotal
Control diet (AIN-76A)974760.09 ± 0.29b1.26 ± 1.111.35 ± 1.10
Celecoxib, 500 ppmc633d, (55)e36d, (53)0.06 ± 0.23f,0.39 ± 0.64f, (69)0.44 ± 0.69f, (67)
Celecoxib, 1000 ppmc028d, (62)28d, (62)00.36 ± 0.64f, (71)0.36 ± 0.64f, (73)
Celecoxib, 1500 ppmc017d, (77)17d, (77)00.22 ± 0.59f, (83)0.22 ± 0.59f, (84)
Celecoxib, 1500 ppmg839d, (47)42d, (45)0.08 ± 0.320.50 ± 0.77f, (60)0.58 ± 0.84f, (57)
  • a Values include both adenomas and adenocarcinomas.

  • b Values represent the mean ± SD.

  • c Celecoxib was administered in the diet beginning 2 weeks before and during carcinogen treatment and until termination of the study at week 52.

  • d Significantly different from the control diet group by Fisher’s exact probability test (1, P < 0.01; 2, P < 0.001; 3, P < 0.0001).

  • e Values in parentheses represent percentage inhibition from the control diet group.

  • f Significantly different from the control diet group by Welch’s t test (1, P < 0.01; 2, P < 0.001; 3, P < 0.0001).

  • g Celecoxib was administered starting 14 weeks after second AOM treatment until termination of the study.